Skip to Content
  • Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.

Journal of Market Access & Health Policy, Volume 4, Issue 1

2016 January - 16 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (16)

  • Essay
  • Open Access
465 Views
3 Pages

It is important to evaluate how the value of medicine is assessed, as it may have important implications for health technology and reimbursement assessments. The value equation could comprise ‘incremental benefit/outcome’ (relative results of care in...

  • Article
  • Open Access
9 Citations
510 Views
6 Pages

A Training Paradigm to Enhance Performance and Safe Use of an Innovative Neuroendovascular Device

  • Donald R. Ricci,
  • Thomas R. Marotta,
  • Howard A. Riina,
  • Martina Wan and
  • Joost De Vries

Training has been important to facilitate the safe use of new devices designed to repair vascular structures. This paper outlines the generic elements of a training program for vascular devices and uses as an example the actual training requirements...

  • Guidelines
  • Open Access
1 Citations
460 Views
10 Pages

The pan-Canadian Oncology Drug Review (pCODR) makes recommendations to Canada's provinces and territories (except Quebec) to guide their cancer drug funding decisions. The objective of this paper is to explore, using an economic perspective and the p...

  • Article
  • Open Access
29 Citations
583 Views
9 Pages

Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders: A Consensus Statement

  • Michael Schlander,
  • Silvio Garattini,
  • Peter Kolominsky-Rabas,
  • Erik Nord and ,
  • Ulf Persson,
  • Maarten Postma,
  • Jeff Richardson,
  • Steven Simoens,
  • Oriol de Solà-Morales and
  • Mondher Toumi
  • + 6 authors+ 1 author

Background: In most jurisdictions, policies have been adopted to encourage the development of treatments for rare or orphan diseases. While successful as assessed against their primary objective, these policies have prompted concerns among payers abo...

  • Article
  • Open Access
432 Views
4 Pages

What Makes a Compliant Phase III and Pre-launch Patient Advocacy Strategy?

  • Nick Hicks,
  • Keith Allan,
  • Christoph Thalheim and
  • Paul Woods

Background: A key task for the pharmaceutical industry is to understand the compliance implications of engaging with a patient advocacy group (PAG). This presents challenges for the industry to negotiate the ethical and reputational issues that can a...

  • Article
  • Open Access
13 Citations
613 Views
11 Pages

Cost-Effectiveness of Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole

  • Craig Bennison,
  • Stephanie Stephens,
  • Benedicte Lescrauwaet,
  • Ben Van Hout and
  • Timothy L. Jackson

Background: If left untreated, vitreomacular traction (VMT) will infrequently improve through spontaneous resolution of vitreomacular adhesion (VMA), and patients remain at risk of further deterioration in vision. The mainstay of treatment for VMT is...

  • Article
  • Open Access
6 Citations
678 Views
9 Pages

Validation of Disease States in Schizophrenia: Comparison of Cluster Analysis between US and European Populations

  • Katia Thokagevistk,
  • Aurélie Millier,
  • Leslie Lenert,
  • Shamil Sadikhov and ,
  • Santiago Moreno and
  • Mondher Toumi
  • + 1 author+ 0 author

Background: There is controversy as to whether use of statistical clustering methods to identify common disease patterns in schizophrenia identifies patterns generalizable across countries. Objective: The goal of this study was to compare disease sta...

  • Article
  • Open Access
109 Citations
1,779 Views
10 Pages

Advanced Therapy Medicinal Products: Current and Future Perspectives

  • Eve Hanna,
  • Cécile Rémuzat,
  • Pascal Auquier and
  • Mondher Toumi

Background: Advanced therapy medicinal products (ATMPs) are innovative therapies that encompass gene therapy, somatic cell therapy, and tissue-engineered products. These therapies are expected to bring important health benefits, but also to substanti...

  • Article
  • Open Access
17 Citations
827 Views
9 Pages

The Value of Innovation under Value-Based Pricing

  • Santiago G. Moreno and
  • Joshua A. Ray

Objective: The role of cost-effectiveness analysis (CEA) in incentivizing innovation is controversial. Critics of CEA argue that its use for pricing purposes disregards the ‘value of innovation’ reflected in new drug development, whereas supporters o...

  • Article
  • Open Access
15 Citations
684 Views
10 Pages

Drug Pricing Reform in China: Analysis of Piloted Approaches and Potential Impact of the Reform

  • Yixi Chen,
  • Shanlian Hu,
  • Peng Dong,
  • Åsa Kornfeld and ,
  • Patrycja Jaros,
  • Jing Yan,
  • Fangfang Ma and
  • Mondher Toumi
  • + 3 authors+ 0 author

Objectives: In 2009, the Chinese government launched a national healthcare reform programme aiming to control healthcare expenditure and increase the quality of care. As part of this programme, a new drug pricing reform was initiated on 1 June 2015....

  • Review
  • Open Access
33 Citations
1,156 Views
7 Pages

Feasibility and Attractiveness of Indication Value-Based Pricing in Key EU Countries

  • Mathias Flume,
  • Marc Bardou,
  • Stefano Capri,
  • Oriol Sola-Morales and ,
  • David Cunningham,
  • Lars-Ake Levin and
  • Nicolas Touchot
  • + 2 authors+ 0 author

Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experi...

  • Article
  • Open Access
14 Citations
568 Views
6 Pages

The Quality of Life of Spanish Patients with Huntington's Disease Measured with H-QoL-I and EQ-5D

  • Julie Dorey,
  • Emilie Clay,
  • Amine Khemiri,
  • Anis Belhadj and ,
  • Patricia Trigo Cubillo and
  • Mondher Toumi
  • + 1 author+ 0 author

Background and objective: Huntington's disease (HD) is an inherited neurodegenerative disorder that heavily affects the patient's motor, cognitive, and psychological functions. Yet, very few studies have measured the impact of this disease on the pat...

  • Article
  • Open Access
14 Citations
923 Views
10 Pages

Background: A change in the pharmaceutical environment has occurred from previously only needing to convince regulators of a product's safety and efficacy to obtain marketing authorisation to now needing to satisfy the value perceptions of other stak...

  • Article
  • Open Access
5 Citations
495 Views
7 Pages

Objective: To explore the relationship between prices charged by manufacturers of proprietary pharmaceuticals in the US and in the UK in recent years (2013–2016), expressed as a multiplier, and to detail to what extent this relationship differs for h...

  • Article
  • Open Access
50 Citations
559 Views
5 Pages

Risk of Discontinuation of Advanced Therapy Medicinal Products Clinical Trials

  • Eve Hanna,
  • Cecile Rémuzat,
  • Pascal Auquier and
  • Mondher Toumi

Objective: Advanced therapy medicinal products (ATMPs) constitute a class of innovative products that encompasses gene therapy, somatic cell therapy, and tissue-engineered products (TEP). There is an increased investment of commercial and non-commerc...

  • Article
  • Open Access
9 Citations
828 Views
15 Pages

Cost-Effectiveness Analysis of the Direct and Indirect Impact of Intranasal Live Attenuated Influenza Vaccination Strategies in Children: Alternative Country Profiles

  • Edward Gibson,
  • Najida Begum,
  • Federico Martinón-Torres,
  • Marco Aurélio Safadi and ,
  • Alfred Sackeyfio,
  • Judith Hackett and
  • Sankarasubramanian Rajaram
  • + 2 authors+ 0 author

Background: Influenza poses a significant burden on healthcare systems and society, with under-recognition in the paediatric population. Existing vaccination policies (largely) target the elderly and other risk groups where complications may arise. O...

XFacebookLinkedIn
J. Mark. Access Health Policy - ISSN 2001-6689